Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 31
Ipamorelin side effects: what trials report
Ipamorelin has no approved label and no official adverse-event profile. Here is what the one human clinical trial and early pharmacokinetic work found.
Is ipamorelin banned in sport? WADA status
Ipamorelin is prohibited in and out of competition under WADA section S2. Here is why S2 applies and what competing athletes need to know.
Is tesamorelin legal? US, EU, and UK status
Tesamorelin is FDA-approved in the US for HIV-associated lipodystrophy. No EU or UK marketing authorisation exists.
Is tirzepatide legal? EU, UK and US status
Tirzepatide is prescription-only in the US, EU, and UK. Here is what legal access looks like across each jurisdiction.
GLP-1 drugs and the 2025 US health bill
US health spending hit $5.7 trillion in 2025, up 7.3%, and GLP-1 drugs like semaglutide and tirzepatide are a named driver. Here is what the numbers say.
One blood test, 54 peptide doping agents
A 2026 Ghent University method screens 54 peptide and non-peptide doping agents, including TB-500 and BPC-157, in dried and liquid blood in a single fast run.
Semaglutide and the cost of CV benefit
A 2026 cost-effectiveness review places semaglutide, a GLP-1 agonist, in the moderate tier for preventing cardiovascular events. Here is what that means.
Semaglutide and heart risk: a 2026 review
A 2026 meta-analysis of 11 trials found semaglutide cut major cardiovascular events by about a third, similarly in people with and without diabetes.
Semaglutide for non-diabetic CKD: review
A 2026 review pooled 3 studies on semaglutide for non-diabetic obesity with kidney disease or hypertension. The signal is early, not long-term.
Semaglutide and the silent HFpEF signal
A 2026 meta-analysis of six trials links semaglutide to lower NT-proBNP, better symptom scores and fewer heart-failure hospitalisations in obesity-driven HFpEF.
How semaglutide works across the body
A 2026 review reads semaglutide through a systems medicine lens, tracing the GLP-1 receptor agonist from trial outcomes to the molecular mediators underneath.
Weight-loss drugs and hypertension
A Cochrane review of eight trials finds insufficient evidence that weight-loss drugs cut mortality or cardiovascular events in hypertensive patients.